Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone Monoaminylation refers to the covalent modification of histone proteins by monoamines (e.g., serotonin, histamine) mediated by transglutaminase 2 (TG2). This process, independent of classical neurotransmission, alters chromatin structure and gene expression, impacting circadian rhythms and potentially contributing to various disease states.
Modulation of gene expression through covalent attachment of monoamines to histone proteins, altering chromatin structure and transcription factor binding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone Monoaminylation.